89bio Announces Additional Data from the ENLIVEN Phase 2b Tr

89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023

89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023

tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

San Francisco , California , United States , Boston , Massachusetts , Sheryl Seapy , Annie Chang , Hank Mansbach , Nasdaq , Linkedin , Exchange Commission , Lifesci Advisors , Drug Administration , Announces Additional Data , Compensated Cirrhotic , Nonalcoholic Steatohepatitis , Liver Meeting , Chief Medical Officer , Non Invasive Tests , Breakthrough Therapy , New England Journal , Breakthrough Therapy Designation , Annual Report , Safe Harbor , Private Securities Litigation Reform Act , Sci Advisors ,